These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1143 related articles for article (PubMed ID: 24231662)

  • 1. The gut microbiome, kidney disease, and targeted interventions.
    Ramezani A; Raj DS
    J Am Soc Nephrol; 2014 Apr; 25(4):657-70. PubMed ID: 24231662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of CKD on Uremic Toxins and Gut Microbiota.
    Rysz J; Franczyk B; Ławiński J; Olszewski R; Ciałkowska-Rysz A; Gluba-Brzózka A
    Toxins (Basel); 2021 Mar; 13(4):. PubMed ID: 33807343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome in chronic kidney disease.
    Wing MR; Patel SS; Ramezani A; Raj DS
    Exp Physiol; 2016 Apr; 101(4):471-7. PubMed ID: 26337794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gut-kidney axis.
    Evenepoel P; Poesen R; Meijers B
    Pediatr Nephrol; 2017 Nov; 32(11):2005-2014. PubMed ID: 27848096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiome in chronic kidney disease: challenges and opportunities.
    Nallu A; Sharma S; Ramezani A; Muralidharan J; Raj D
    Transl Res; 2017 Jan; 179():24-37. PubMed ID: 27187743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiota issue in CKD: how promising are gut-targeted approaches?
    Cosola C; Rocchetti MT; Sabatino A; Fiaccadori E; Di Iorio BR; Gesualdo L
    J Nephrol; 2019 Feb; 32(1):27-37. PubMed ID: 30069677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].
    Han WB; Liu YL; Wan YG; Sun W; Tu Y; Yang JJ; Wu W; He WM; Yao J
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2425-2432. PubMed ID: 28840678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics.
    Vitetta L; Gobe G
    Mol Nutr Food Res; 2013 May; 57(5):824-32. PubMed ID: 23450842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal microbiota alterations in chronic kidney disease and the influence of dietary components.
    Ondrussek-Sekac M; Navas-Carrillo D; Orenes-Piñero E
    Crit Rev Food Sci Nutr; 2021; 61(9):1490-1502. PubMed ID: 32393049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homeostasis in the Gut Microbiota in Chronic Kidney Disease.
    Bhargava S; Merckelbach E; Noels H; Vohra A; Jankowski J
    Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota in chronic kidney disease.
    Cigarran Guldris S; González Parra E; Cases Amenós A
    Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gut microbiota and its relationship with chronic kidney disease.
    Plata C; Cruz C; Cervantes LG; Ramírez V
    Int Urol Nephrol; 2019 Dec; 51(12):2209-2226. PubMed ID: 31576489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.
    Briskey D; Tucker P; Johnson DW; Coombes JS
    Clin Exp Nephrol; 2017 Feb; 21(1):7-15. PubMed ID: 26965149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease.
    Mafra D; Lobo JC; Barros AF; Koppe L; Vaziri ND; Fouque D
    Future Microbiol; 2014; 9(3):399-410. PubMed ID: 24762311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Uremic toxins and gut micro biome].
    Vaziri ND; Suematsu Y; Shimomura A; Vaziri ND
    Nihon Jinzo Gakkai Shi; 2017; 59(4):535-544. PubMed ID: 30620802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial.
    Ramos CI; Armani RG; Canziani MEF; Dalboni MA; Dolenga CJR; Nakao LS; Campbell KL; Cuppari L
    Nephrol Dial Transplant; 2019 Nov; 34(11):1876-1884. PubMed ID: 29939302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling.
    Vitetta L; Linnane AW; Gobe GC
    Toxins (Basel); 2013 Nov; 5(11):2042-57. PubMed ID: 24212182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of intestinal barrier and microbiota in chronic kidney disease.
    Sabatino A; Regolisti G; Brusasco I; Cabassi A; Morabito S; Fiaccadori E
    Nephrol Dial Transplant; 2015 Jun; 30(6):924-33. PubMed ID: 25190600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microbiota and prebiotics modulation of uremic toxin generation.
    Koppe L; Fouque D
    Panminerva Med; 2017 Jun; 59(2):173-187. PubMed ID: 28001024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-chain fatty acids: a link between prebiotics and microbiota in chronic kidney disease.
    Esgalhado M; Kemp JA; Damasceno NR; Fouque D; Mafra D
    Future Microbiol; 2017 Nov; 12():1413-1425. PubMed ID: 29027814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.